| Literature DB >> 7033575 |
B S Hulka, L E Chambless, D G Kaufman, W C Fowler, B G Greenberg.
Abstract
Seventy-nine patients with endometrial carcinoma were compared with 203 control subjects regarding their use of combination-product oral contraceptives (OCs). Overall, 6.3% of patients and 15.3% of control subjects had used these products. The risk of endometrial cancer for users of OCs was less than half the risk for nonusers. Five years or more of use reduced the risk to a third. Recent users were strongly protected, whereas discontinuation resulted in risks returning to those of nonusers. Furthermore, OCs with predominantly progestational effects of intermediate formulations produced greater protection than those with predominantly estrogens. This pattern of results is biologically consistent with a protective effect of combination-product OCs against endometrial carcinoma.Entities:
Keywords: Age Factors; Americas; Cancer; Case Studies; Contraception; Contraceptive Methods; Contraceptive Methods--side effects; Control Groups; Developed Countries; Diabetes Mellitus; Diseases; Endometrial Cancer; Ethnic Groups; Family Planning; Hypertension; Neoplasms; North America; North Carolina; Northern America; Obesity; Oral Contraceptives, Combined; Oral Contraceptives--side effects; Parity; Research Methodology; Studies; United States
Mesh：
Substances：
Year: 1982 PMID： 7033575
Source DB: PubMed Journal: JAMA ISSN： 0098-7484 Impact factor: 56.272